DV Biomed Co., Ltd.

TPEX:6539 株式レポート

時価総額：NT$1.4b

DV Biomed 過去の業績

過去 基準チェック /16

DV Biomed's earnings have been declining at an average annual rate of -3.2%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been declining at an average rate of 6.1% per year. DV Biomed's return on equity is 22.8%, and it has net margins of 3.6%.

主要情報

-3.2%

収益成長率

-2.6%

EPS成長率

Biotechs 業界の成長12.2%
収益成長率-6.1%
株主資本利益率22.8%
ネット・マージン3.6%
前回の決算情報30 Jun 2024

最近の業績更新

DV Biomed's (GTSM:6539) Earnings Are Growing But Is There More To The Story?

Jan 07
DV Biomed's (GTSM:6539) Earnings Are Growing But Is There More To The Story?

Recent updates

How Does DV Biomed Co., Ltd. (GTSM:6539) Stand Up To These Simple Dividend Safety Checks?

Mar 22
How Does DV Biomed Co., Ltd. (GTSM:6539) Stand Up To These Simple Dividend Safety Checks?

DV Biomed Co., Ltd.'s (GTSM:6539) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Jan 27
DV Biomed Co., Ltd.'s (GTSM:6539) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

DV Biomed's (GTSM:6539) Earnings Are Growing But Is There More To The Story?

Jan 07
DV Biomed's (GTSM:6539) Earnings Are Growing But Is There More To The Story?

Should DV Biomed (GTSM:6539) Be Disappointed With Their 37% Profit?

Dec 10
Should DV Biomed (GTSM:6539) Be Disappointed With Their 37% Profit?

Are You An Income Investor? Don't Miss Out On DV Biomed Co., Ltd. (GTSM:6539)

Nov 19
Are You An Income Investor? Don't Miss Out On DV Biomed Co., Ltd. (GTSM:6539)

収支内訳

DV Biomed の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

TPEX:6539 収益、費用、利益 ( )TWD Millions
日付収益収益G+A経費研究開発費
30 Jun 241,4625355011
31 Mar 241,50010356411
31 Dec 231,53815357812
30 Sep 231,16120751011
30 Jun 231,27226252012
31 Mar 231,56927557912
31 Dec 221,86628963913
30 Sep 221,86330562413
30 Jun 221,85932160912
31 Mar 221,84331360012
31 Dec 211,82730559112
30 Sep 211,83628160112
30 Jun 211,84525761111
31 Mar 211,82827961921
31 Dec 201,81230162632
30 Sep 201,81125165455
30 Jun 201,76523964379
31 Mar 201,84820367692
31 Dec 191,930166709105
30 Sep 191,949192694108
30 Jun 191,92615472496
31 Mar 191,89614972586
31 Dec 181,86614472675
30 Sep 181,78017667163
30 Jun 181,77923361363
31 Mar 181,59421352757
31 Dec 171,40919344151
30 Sep 171,25216738045
30 Jun 171,09414231938
31 Mar 171,05016926536
31 Dec 161,00319421235
30 Sep 1698320719839
30 Jun 1696422018443
31 Mar 1688721318340
31 Dec 1583020716934
30 Sep 1575118017328
30 Jun 1567315217722
31 Mar 1555310515322
31 Dec 144176114122
31 Dec 13131154810

質の高い収益: 6539 has a high level of non-cash earnings.

利益率の向上: 6539's current net profit margins (3.6%) are lower than last year (20.6%).

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 6539's earnings have declined by 3.2% per year over the past 5 years.

成長の加速: 6539's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

収益対業界: 6539 had negative earnings growth (-79.9%) over the past year, making it difficult to compare to the Biotechs industry average (33.2%).

株主資本利益率

高いROE: 6539's Return on Equity (22.8%) is considered high.

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y